While we keep our projects under development in stealth mode, we are thrilled to showcase our first spin-off, TAG Therapeutics.
TAG Therapeutics is dedicated to addressing telomere pathologies and age-related disorders through its Teloblock™ platform.
Originating from the innovative research of Dr. Fabrizio d'Adda di Fagagna at IFOM and accelerated through Danube Labs, our preclinical acceleration programme, developed in collaboration with Evotec, leverages antisense oligonucleotide (ASO)-based precision medicine to combat telomere dysfunction. This approach targets conditions such as Idiopathic Pulmonary Fibrosis (IPF) and Short Telomere Syndromes.
We are excited about TAG's potential to transform the treatment landscape for telomere-related diseases, offering new hope to patients worldwide..
